What is the Fiscal Year for Belite Bio?
Date: November 14, 2026
Belite Bio's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
San Diego, California
Industry
Biotechnology Research
Stock Symbol
BLTE
Website
http://www.belitebio.comDescription
Belite Bio (NASDAQ: BLTE) is a San Diego based clinical stage drug development company targeting untreatable eye diseases, such as dry AMD and Stargardt disease (STGD1) which is the most common inherited retinal dystrophy, and metabolic diseases. Its lead pipeline, Tinlarebant (aka LBS-008), is a novel oral once-a-day tablet intended to treat Dry AMD and STGD1 early. Tinlarebant is in phase 3 and has been granted Fast Track & RPD designation in the US, and ODD in the US and EMA for STGD1.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Belite Bio and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.